Regulation of Fas ligand expression in breast cancer cells by estrogen: Functional differences between estradiol and tamoxifen

Journal of Steroid Biochemistry and Molecular Biology

Volumn 73, Issue 5, 2000, Pages 185-194

  Mor, Gil ^a   Kohen, Fortune ^b   Garcia Velasco, Juan ^a   Nilsen, Jon ^a   Brown, Wendi ^a   Song, Joon ^a   Naftolin, Frederick ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

Breast cancer; Estrogen; FasL; Tamoxifen

Indexed keywords

COMPLEMENTARY DNA; ESTRADIOL; ESTROGEN RECEPTOR; FAS LIGAND; MESSENGER RNA; TAMOXIFEN; VITELLOGENIN;

ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; BREAST CANCER; CELL STRAIN MCF 7; CONTROLLED STUDY; DRUG CYTOTOXICITY; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE ACTIVATION;

ANTIGENS, CD95; BREAST NEOPLASMS; ESTRADIOL; FAS LIGAND PROTEIN; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MEMBRANE GLYCOPROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TAMOXIFEN; TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED;

EID: 0033744678     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-0760(00)00081-9     Document Type: Article

References (58)

1. Growth factors in breast cancer
2. Steroid hormones and human cancer
3. Cytokines in endocrinology
4. The future of antihormone therapy: Innovations based on an established principle
5. Breast cancer and the role of cytokines in regulating estrogen synthesis: An emerging hypothesis
6. The beneficial effects of treatment with tamoxifen and anti-oestradiol antibody on experimental systemic lupus erythematosus are associated with cytokine modulations
7. Cytokine networks in solid human tumors: Regulation of angiogenesis
8. Oestrogen, menopause and the immune system
9. An immune suppressive factor derived from esophageal carcinoma squamous carcinoma induces apoptosis in normal and transformed cells of lymphoid lineage
10. Gangliosides and antitumor immunity
11. Deacetylase activity of human tumor cells producing immunosuppressive aminosugars: Its possible role in resistance to cell mediated cytotoxicity
12. Fas-Fas ligand system induced apoptosis in human placenta and gestational trophoblastic disease
13. Fas ligand expression in normal, hyperplastic and neoplastic prostate
14. Fas-Fas ligand-based interactions between tumor cells and tumor-specific cytotoxic T lymphocytes - A lethal two-way street
15. The Fas death factor
16. Interferon γ-inducing factor, a novel cytokine, enhances Fas ligand-mediated cytotoxicity of murine T helper 1 cells
17. Membrane Fas ligand kills human peripheral blood T lymphocytes, and soluble Fas ligand blocks the killing
18. The cDNA structure, expression and chromosomal assignment of the mouse Fas antigen
19. Fas-ligand: Privilege and peril
20. A role for CD95 ligand in preventing graft rejection
21. The role of FasL-induced apoptosis in immune privilege
22. Good, Trophoblasts express Fas ligand: A proposed mechanism for immune privilege in placenta and maternal invasion
23. Melanoma cell expression of Fas (Apo-1/CD95) ligand: Implications for tumor immune escape
24. Constitutive expression of Fas (Apo-1/Cd95) ligand on multiple myeloma cells - A potential mechanism of tumor-induced suppression of immune surveillance
25. The Fas counter attack: Fas mediated T cell killing by colon cancer cells expressing Fas ligand
26. The Fas/Fas-Ligand system: A mechanism for immune evasion in human breast carcinomas
27. Lymphocyte apoptosis induced by CD95 (APO-1 Fas) ligand-expressing tumor cells - A mechanism of immune evasion?
28. Cytokines in rodent reproduction and the cytokine-endocrine interaction
29. Evidence for the presence of estrogen receptor in monocytes
30. FasL (CD95L, Apo1L) is expressed in the normal rat and human brain-evidence for the existence of an immunological brain barrier
31. APO-1 (CD95)-dependent and -independent antigen receptor-induced apoptosis in human T and B cell lines
32. The JAM test
33. Regulation of the proinflammatory effects of Fas ligand (CD95L)
34. Local Fas/APO-1 (CD95) ligand-mediated tumor cell killing in vivo
35. Fas ligand induces apoptosis as a mechanism of immune privilege
36. Lymphocyte apoptosis induced by Fas ligand-expressing ovarian carcinoma cells. Implications for altered expression of T cell receptor in tumor-associated lymphocytes
37. The CD-95 (Apo-1/Fas) system mediates drug induced apoptosis in neuroblastoma cells
38. Macrophages, estrogen and the microenvironment of breast cancer
39. Identification of an estrogen response element upstream of the human c-fos gene that binds the estrogen receptor and the AP-1 transcription factor
40. Role of the Fas/Fas ligand pathway in apoptotic cell death induced by the human T cell lymphotrophic virus type 1 Tax transactivator
41. Sequence requirements for estrogen receptor binding to estrogen response elements
42. The thyroid hormone receptor binds with opposite transcriptional effects to a common sequence motif in thyroid hormone and estrogen response elements
43. Estrogen-responsive element of the human pS2 gene is an imperfectly palindromic sequence
44. Novel estrogen response elements identified by genetic selection in yeast are differentially responsive to estrogens and antiestrogens in mammalian cells
45. Cellular mechanisms which distinguish between hormone- and antihormone-activated estrogen receptor
46. Tamoxifen down-regulates CD36 messenger RNA levels in normal and neoplastic human breast tissues
47. Decrease in c-erbB-2 and c-myc RNA levels in Tamoxifen-treated breast cancer
48. P53-dependent DNA damage-induced apoptosis requires Fas/Apo-1-independent activation of Cpp32-beta
49. Transcription factor interactions: Selectors of positive or negative regulation from a single DNA element
50. Joints in the regulatory lattice: Composite regulation by steroid receptor-AP1 complexes
51. Retinoic acid is a negative regulator of AP-1-responsive genes
52. Characterization of DNA binding and retinoic acid binding properties of retinoic acid receptor
53. Activation of the ovalbumin gene by the estrogen receptor involves the fos-jun complex
54. The c-Fos protein interacts with c-Jun/AP-1 to stimulate transcription of AP-1 responsive genes
55. The Fos and Jun/AP-1 proteins are involved in the downregulation of Fos transcription
56. Jun-B differs in its biological properties from, and is a negative regulator of, c-Jun
57. Targets for signal-transducing protein kinases
58. Differential ligand activation of estrogen receptors ERα and ERβ at AP1 sites